Middle East and Africa Human Leukocyte Antigen (HLA) Typing for Transplant Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Middle East and Africa Human Leukocyte Antigen (HLA) Typing for Transplant Market Size

• The Middle East and Africa Human Leukocyte Antigen (HLA) typing for transplant market size was valued at USD 18.92 million in 2025 and is expected to reach USD 29.03 million by 2033, at a CAGR of 5.50% during the forecast period
• The market growth in the region is largely fueled by increasing adoption of transplant procedures, rising healthcare investments, and expanding laboratory capabilities that support organ and stem cell transplant matching, driving demand for precise tissue‑typing solutions in both clinical and transplant center settings
• Furthermore, growing awareness of genetic compatibility testing, technological progress in molecular assay methods, and expanding healthcare infrastructure across Middle Eastern and African countries are encouraging the uptake of HLA typing solutions, positioning this segment as an essential component of modern transplant diagnostics and care

Middle East and Africa Human Leukocyte Antigen (HLA) Typing for Transplant Market Analysis

• HLA typing, providing precise tissue-matching analysis for organ and stem cell transplants, is increasingly vital for improving transplant success rates and reducing graft rejection in both hospitals and transplant centers across the Middle East and Africa, due to its critical role in personalized transplant care and clinical decision-making
• The escalating demand for HLA typing is primarily fueled by rising organ and stem cell transplant procedures, growing awareness of genetic compatibility testing, and expanding healthcare infrastructure, which are driving the adoption of advanced HLA typing solutions in the region
• Saudi Arabia dominated the Middle East and Africa Human Leukocyte Antigen (HLA) typing for transplant market with the largest revenue share of 38.5% in 2025, characterized by high patient volumes, advanced laboratory capabilities, and increasing integration of HLA testing into routine transplant protocols
• Egypt is expected to be the fastest-growing country in the Middle East and Africa Human Leukocyte Antigen (HLA) typing for transplant market during the forecast period due to rising investments in healthcare infrastructure, improved access to diagnostic laboratories, and government initiatives promoting organ and stem cell transplantation programs
• Reagents and consumables segment dominated the Middle East and Africa Human Leukocyte Antigen (HLA) typing for transplant market with a market share of 48.9% in 2025, driven by recurring demand for assay kits, laboratory consumables, and testing supplies required for routine HLA typing procedures in transplant diagnostics

Report Scope and Middle East and Africa Human Leukocyte Antigen (HLA) Typing for Transplant Market Segmentation

Middle East and Africa Human Leukocyte Antigen (HLA) Typing for Transplant Market Trends

Advancement Through Sequencing-Based and Molecular Assay Integration

• A significant and accelerating trend in the MEA HLA typing market is the growing adoption of sequencing-based molecular assays and advanced molecular assay technologies, enabling highly accurate and rapid tissue-matching analysis for organ and stem cell transplants
  • For instance, Illumina’s TruSight HLA sequencing kit allows transplant centers to perform high-resolution typing of multiple loci, improving donor-recipient compatibility assessments
• Integration of molecular assays enables features such as detection of rare HLA alleles, faster turnaround times, and automated workflow integration, enhancing clinical decision-making and transplant success rates
• The seamless combination of HLA typing with hospital laboratory information systems facilitates centralized patient data management, reporting, and real-time decision support in transplant centers
• This trend towards more precise, automated, and high-throughput HLA typing systems is reshaping standards for transplant diagnostics, with companies such as Thermo Fisher Scientific developing solutions compatible with next-generation sequencing platforms
• The demand for HLA typing solutions that offer advanced sequencing and molecular assay integration is growing rapidly across hospitals and transplant centers, as healthcare providers prioritize transplant safety and efficiency
• Furthermore, integration with bioinformatics and AI-driven analytics is emerging, enabling predictive insights for donor-recipient matching and post-transplant monitoring
•  The growing focus on personalized medicine and transplant immunology research is driving investments in advanced HLA typing technologies
• Increased government funding and public-private partnerships are promoting the adoption of high-resolution HLA typing for better transplant outcomes and patient care

Middle East and Africa Human Leukocyte Antigen (HLA) Typing for Transplant Market Dynamics

Driver

Rising Transplant Procedures and Growing Awareness of Genetic Compatibility

• The increasing number of organ and stem cell transplant procedures, coupled with rising awareness of genetic compatibility testing, is a significant driver for the heightened demand for HLA typing in the MEA region
  • For instance, King Faisal Specialist Hospital in Saudi Arabia expanded its HLA typing services to support increasing stem cell transplant volumes, reflecting the growing clinical adoption of advanced tissue-typing solutions
• As transplant centers and hospitals seek to improve graft survival and patient outcomes, HLA typing offers critical information for donor-recipient matching, reducing graft rejection risks, and optimizing immunosuppressive therapy
• Furthermore, increasing investments in healthcare infrastructure and laboratory capabilities are making HLA typing an integral part of transplant programs, offering seamless integration with other diagnostic workflows
• The combination of improved clinical outcomes, growing transplant volumes, and government-supported healthcare initiatives is propelling the adoption of HLA typing solutions in hospitals and transplant centers across MEA
• Rising collaborations between diagnostic companies and regional healthcare providers are further driving adoption by improving service reach and operational efficiency
• The increasing trend of private hospital chains expanding advanced transplant services is also contributing to market growth by creating demand for reliable and high-throughput HLA typing solutions
• The growing emphasis on early detection and pre-transplant risk assessment is increasing the need for accurate HLA typing
• Expanding medical tourism for transplants in countries such as UAE and Saudi Arabia is creating additional demand for high-quality HLA typing services

Restraint/Challenge

High Costs and Limited Laboratory Access in Certain Countries

• Concerns surrounding the relatively high cost of advanced HLA typing assays and limited access to fully equipped molecular laboratories pose significant challenges to broader market penetration
  • For instance, some smaller hospitals in Egypt or Sub-Saharan Africa face difficulties implementing high-resolution HLA typing due to the need for expensive reagents, instruments, and trained personnel
• Addressing these challenges through cost-effective assay kits, modular laboratory solutions, and centralized testing services is crucial for expanding access across the region
• In addition, limited trained personnel and stringent regulatory requirements in some MEA countries can slow adoption rates, making it necessary for companies to provide technical support and training programs
• Overcoming these cost and infrastructure barriers, along with targeted awareness campaigns and capacity-building initiatives, will be vital for sustained growth in the HLA typing market
• Variability in reimbursement policies across countries can also restrict adoption, as some patients may face high out-of-pocket costs for HLA testing
• Logistical challenges in transporting samples from remote areas to centralized laboratories can delay results, limiting timely donor-recipient matching and affecting overall transplant outcomes
• Limited awareness among smaller clinics and patients about the importance of HLA typing for transplant success can hinder market growth
• Challenges related to standardization and quality control across different laboratories may impact the reliability and adoption of HLA typing services

Middle East and Africa Human Leukocyte Antigen (HLA) Typing for Transplant Market Scope

The market is segmented on the basis of products and services, technology, transplant type, application, and end user.

•  By Products and Services

On the basis of products and services, the market is segmented into reagents and consumables, instruments, and software and services. The Reagents and Consumables segment dominated the market with the largest revenue share of 48.9% in 2025, driven by the recurring need for assay kits, laboratory consumables, and testing supplies required for routine HLA typing procedures. Hospitals and transplant centers consistently demand reagents for high-throughput testing, ensuring accurate donor-recipient matching. Reagents also include PCR kits, primers, and sequencing kits, which are essential for both sequencing-based and molecular assay workflows. In addition, consumables such as microplates, pipette tips, and sample tubes create recurring revenue streams, making this segment highly stable. The consistent adoption across established hospitals in Saudi Arabia and UAE contributes to its dominance. The availability of high-quality, ready-to-use reagents also reduces operational complexity and improves turnaround times, further solidifying this segment’s leading position.

The Instruments segment is anticipated to witness the fastest growth rate from 2026 to 2033, fueled by rising adoption of automated HLA typing platforms and next-generation sequencing instruments in both hospitals and reference laboratories. Instruments such as sequencing machines, PCR thermocyclers, and automated analyzers allow laboratories to perform high-resolution typing with reduced manual intervention. This reduces human error, enhances throughput, and supports timely donor-recipient matching, which is critical for successful transplants. The growth is particularly strong in Egypt and South Africa, where laboratories are investing in advanced diagnostic instruments to meet rising transplant demand. Moreover, technological innovations such as compact, bench-top sequencing platforms make instruments more accessible to smaller hospitals and research centers, accelerating adoption.

• By Technology

On the basis of technology, the market is segmented into sequencing-based molecular assays, molecular assay technologies, and non-molecular assay technologies. The Molecular Assay Technologies segment dominated the market in 2025, capturing the largest revenue share due to its high accuracy and proven reliability in routine HLA typing for both solid organ and stem cell transplants. These assays include PCR-based methods, SSO (sequence-specific oligonucleotide), and SSP (sequence-specific primer) assays that are widely implemented in hospitals and reference laboratories. Hospitals in Saudi Arabia and UAE rely on molecular assay technologies for their balance of cost-effectiveness and high precision. Molecular assays are also compatible with automation, reducing hands-on time and increasing lab efficiency. Their widespread adoption is further driven by regulatory approvals and long-standing clinical validation. The segment benefits from consistent use in diagnostic workflows, providing predictable revenue for suppliers.

The Sequencing-Based Molecular Assays segment is expected to witness the fastest growth during the forecast period, driven by increasing adoption of next-generation sequencing (NGS) in transplant centers and research laboratories. Sequencing-based assays enable high-resolution HLA typing and detection of rare alleles that traditional molecular assays may miss. This technology is particularly in demand in Egypt and South Africa, where medical institutions aim to match international transplant standards. The ability to integrate sequencing data with bioinformatics tools for predictive transplant outcomes further boosts adoption. Rising awareness of its clinical advantages, coupled with decreasing instrument costs and increased availability of sequencing kits, is expected to accelerate growth in this segment.

• By Transplant Type

On the basis of transplant type, the market is segmented into solid organ transplant and haematopoietic stem cell transplant. The Solid Organ Transplant segment dominated the market in 2025, owing to the higher volume of kidney, liver, and heart transplants performed in Saudi Arabia and UAE. Solid organ transplants require precise HLA matching to prevent graft rejection and improve long-term patient outcomes. Hospitals conducting high volumes of these procedures rely heavily on HLA typing services, creating consistent demand for reagents, instruments, and software solutions. Increasing organ transplant programs, government-supported healthcare initiatives, and advanced laboratory infrastructure further contribute to the segment’s dominance. Solid organ transplant typing also benefits from integration with electronic medical records and transplant management systems, facilitating efficient patient monitoring.

The Haematopoietic Stem Cell Transplant segment is expected to witness the fastest growth from 2026 to 2033, driven by rising stem cell transplant procedures in Egypt, South Africa, and UAE. Stem cell transplants require ultra-high-resolution HLA matching, increasing demand for advanced molecular and sequencing-based assays. Growth is fueled by awareness campaigns on stem cell therapy, expansion of specialized transplant centers, and increasing investments in diagnostic laboratories capable of supporting complex typing procedures. The segment’s growth is further supported by emerging medical tourism for stem cell transplants and collaborations with international HLA typing providers.

• By Application

On the basis of application, the market is segmented into diagnostic applications and research applications. The Diagnostic Applications segment dominated the market in 2025, driven by its direct use in pre-transplant donor-recipient matching, risk assessment, and post-transplant monitoring in hospitals and transplant centers. Hospitals in Saudi Arabia and UAE rely on diagnostic HLA typing to ensure graft survival and reduce complications. This segment benefits from recurring demand as each transplant case requires multiple tests for accuracy. It also includes workflow integration with hospital information systems and real-time reporting, which increases adoption and revenue. The growing number of transplant procedures and improved healthcare infrastructure support the segment’s dominance.

The Research Applications segment is expected to witness the fastest growth during the forecast period, fueled by rising academic research in transplant immunology, HLA genomics, and personalized medicine. Research laboratories and academic institutes in Egypt and South Africa are increasingly using HLA typing to study population-specific allele distributions and optimize donor registries. Advancements in sequencing technologies and bioinformatics tools further enhance research applications. Increased funding for transplant-related research and collaborations with diagnostic companies accelerate the adoption of high-resolution HLA typing for research purposes.

• By End User

On the basis of end user, the market is segmented into independent reference laboratories, hospitals and transplant centres, and research laboratories and academic institutes. The Hospitals and Transplant Centres segment dominated the market in 2025, with the largest revenue share due to high patient volumes, advanced laboratory infrastructure, and integration of HLA typing in routine transplant workflows. Hospitals in Saudi Arabia and UAE lead the adoption of high-resolution HLA typing to ensure better graft outcomes. This segment benefits from recurring demand, government support, and consistent adoption of advanced technologies. Hospital-based laboratories also adopt reagents, instruments, and software for centralized patient management, contributing to revenue growth.

The Independent Reference Laboratories segment is expected to witness the fastest growth from 2026 to 2033, driven by outsourcing of HLA typing services from smaller hospitals and clinics in Egypt, South Africa, and UAE. Reference labs provide high-throughput testing, access to advanced molecular and sequencing technologies, and faster turnaround times. Growing awareness of the benefits of centralized HLA typing services, coupled with partnerships with hospitals and research institutes, further accelerates growth in this segment.

Middle East and Africa Human Leukocyte Antigen (HLA) Typing for Transplant Market Regional Analysis

• Saudi Arabia dominated the Middle East and Africa Human Leukocyte Antigen (HLA) typing for transplant market with the largest revenue share of 38.5% in 2025, characterized by high patient volumes, advanced laboratory capabilities, and increasing integration of HLA testing into routine transplant protocols
• Hospitals and transplant centers in the country place significant emphasis on precise donor-recipient matching, which has increased the adoption of molecular and sequencing-based HLA typing solutions to improve graft survival rates and patient outcomes
• This widespread adoption is further supported by government initiatives promoting organ and stem cell transplantation, collaborations with international diagnostic companies, and investments in laboratory automation, establishing HLA typing as an essential diagnostic service in both hospitals and specialized transplant centers

The Saudi Arabia Human Leukocyte Antigen (HLA) Typing for Transplant Market Insight

The Saudi Arabia HLA typing market captured the largest revenue share of 38.5% in 2025, fueled by the country’s advanced healthcare infrastructure, high-volume organ and stem cell transplant programs, and integration of high-resolution HLA typing into clinical workflows. Hospitals and transplant centers increasingly prioritize precise donor-recipient matching, driving the adoption of molecular and sequencing-based HLA typing solutions. Government support, collaborations with international diagnostic companies, and investments in laboratory automation further accelerate market growth. The rising number of specialized transplant centers also strengthens the market’s expansion.

United Arab Emirates (UAE) Human Leukocyte Antigen (HLA) Typing for Transplant Market Insight

The UAE HLA typing market is anticipated to grow at a substantial CAGR during the forecast period, driven by increasing organ and stem cell transplants, strong healthcare investments, and adoption of cutting-edge diagnostic technologies. Hospitals and transplant centers emphasize rapid, accurate HLA typing to improve graft outcomes. The country’s advanced laboratory infrastructure, coupled with public-private partnerships, supports the growth of high-throughput and sequencing-based HLA typing services. Rising medical tourism for transplants further contributes to market expansion.

Egypt Human Leukocyte Antigen (HLA) Typing for Transplant Market Insight

The Egypt HLA typing market is poised for fast growth due to rising awareness of transplant compatibility, expansion of transplant programs, and government initiatives supporting healthcare modernization. Hospitals and reference laboratories are increasingly adopting molecular assay and sequencing-based technologies to enhance transplant success rates. International collaborations and capacity-building programs help improve access to advanced HLA typing, particularly in urban centers. The growing trend of research in transplant immunology and population-specific HLA studies also drives adoption.

South Africa Human Leukocyte Antigen (HLA) Typing for Transplant Market Insight

The South Africa HLA typing market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing stem cell and organ transplant procedures, investment in laboratory infrastructure, and rising demand for precision diagnostics. Hospitals and reference laboratories are upgrading to high-resolution HLA typing technologies to improve donor-recipient matching. Public health initiatives, awareness campaigns, and collaborations with international diagnostics providers promote adoption. Research and academic institutions are also contributing to growth through advanced immunogenetics studies.

Middle East and Africa Human Leukocyte Antigen (HLA) Typing for Transplant Market Share

The Middle East and Africa Human Leukocyte Antigen (HLA) Typing for Transplant industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc. (U.S.)
• QIAGEN (Netherlands)
• Illumina, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• BD (U.S.)
• Luminex Corporation (U.S.)
• CareDx, Inc. (U.S.)
• Immucor, Inc. (U.S.)
• BAG Diagnostics GmbH (Germany)
• inno-train Diagnostik GmbH (Germany)
• CeGaT GmbH (Germany)
• Bionobis (France)
• ProImmune Ltd (U.K.)
• Eurofins Scientific SE (Luxembourg)
• HistoGenetics, Inc. (U.S.)
• Immudex (Denmark)
• GenDx (Netherlands)
• DiaSorin S.p.A. (Italy)
• Omixon Biocomputing Ltd (Hungary)

What are the Recent Developments in Middle East and Africa Human Leukocyte Antigen (HLA) Typing for Transplant Market?

• In July 2025, the Abu Dhabi Biobank announced completion of HLA typing for all stored stem cell samples, bringing the UAE closer to matching patients with locally banked donors and enabling the country to perform its own stem cell transplants without relying on overseas donors. This milestone signifies a major step forward in building regional transplant self‑sufficiency and reducing reliance on external registries
• In May 2025, Abu Dhabi Biobank was reported to be positioning itself as a regional leader in stem cell therapy and research, supported by a state‑of‑the‑art biobank that uses HLA typing to improve donor‑recipient matching. The facility’s development supports personalized treatment and reduces the need for UAE patients to seek transplants abroad, indicating broadening clinical adoption of HLA‑linked transplant diagnostics in the region
• In January 2025, the Middle East Society for Organ Transplantation (MESOT) expanded its activities, including increased publication and professional networking across 29 countries in the Middle East and North Africa, fostering shared research, clinical practice improvements, and transplant expertise a context that supports growth in HLA typing adoption and standardization across the region
• In May 2023, researchers in the United Arab Emirates developed a prototype Calculated Panel Reactive Antibody (CPRA) calculator based on HLA antigen frequencies specific to the UAE population, aimed at improving access to transplantation for highly sensitized patients by more accurately predicting donor compatibility than existing Western calculators
• In April 2021, the Al Jalila Foundation launched a transplant support campaign in the UAE, which by 2025 had backed dozens of kidney and liver transplants. Such programs increase demand for accurate HLA matching as transplant volumes grow, reinforcing the clinical importance of HLA testing infrastructure

SKU-66512